Truist Raises AMN Healthcare Price Target to $45 From $40
Truist maintained its Buy rating and raised its price target to $45 from $40. The firm cited AMN Healthcare’s recent third-quarter results and fourth-quarter guidance.
Truist maintained its Buy rating and raised its price target to $45 from $40. The firm cited AMN Healthcare’s recent third-quarter results and fourth-quarter guidance.